La innovación incremental en salud en España durante la pandemia de la COVID-19

BACKGROUND: It is important to understand the impact of the COVID-19 pandemic on incremental innovation and its protection through industrial property rights, in order to acquiring valuable insights to develop effective public policies and corporate strategies. The objective was to analyze incremental innovations in response to the pandemic that have been protected by industrial property rights, and to examine whether the COVID-19 pandemic had a positive or negative effect on incremental innovation, promoting or inhibiting it. METHODS: Utility models in the health patent class have been used as indicators (01.01.20 to 31.12.21), since the information they provide and their characteristics (requirements of applications and publication) allowed us to obtain preliminary conclusions in the short term. Their frequency of application during the pandemic months was analyzed and compared with an equivalent period immediately before (01.01.18 to 31.12.19). RESULTS: The analysis showed that there had been greater activity in healthcare innovation by all agents (individuals, companies and the public sector). In the pandemic period of 2020-2021, 754 utility models were requested, representing a nearly 40% increase compared to the equivalent period of 2018-2019, of which 284 were identified as pandemic-related innovations, with 59.7% of rights holders being individuals, 36.4% being companies, and only 3.9% being public entities. CONCLUSIONS: In general, incremental innovations require less investment and shorter technology maturation times, which had made it possible to respond, in some cases successfully, to situations of initial shortages of many medical devices, such as ventilators and protective equipment.